Literature DB >> 32074279

Presentation of BK polyomavirus-associated hemorrhagic cystitis after allogeneic hematopoietic cell transplantation.

Hannah Imlay1,2,3, Hu Xie1, Wendy M Leisenring1, Elizabeth R Duke1,2, Louise E Kimball1, Meei-Li Huang1, Steven A Pergam1,2, Joshua A Hill1,2, Keith R Jerome1,4, Filippo Milano1,2, W Garrett Nichols5, Phillip S Pang6, Hans H Hirsch7, Ajit P Limaye2, Michael Boeckh1,2.   

Abstract

BK polyomavirus (BKPyV) has been associated with hemorrhagic cystitis (HC) after allogeneic hematopoietic cell transplantation (HCT), but the natural history of HC and factors associated with the clinical course are incompletely understood. We retrospectively analyzed allogeneic HCT patients transplanted from 2007-2017 who presented after platelet engraftment or after day 28 post-HCT with BKPyV-associated HC (BKPyV-HC), which was defined as a positive urine BKPyV PCR, ≥1 plasma BKPyV viral load result, and macroscopic hematuria (Bedi grade ≥2). Factors associated with resolution of macroscopic hematuria and resolution of all cystitis symptoms within 90 days after HC diagnosis were investigated in multivariable models. In 128 patients with BKPyV-HC, the median times from diagnosis to resolution of all symptoms, macroscopic hematuria, and urinary clots (present in 55% [71/128]) were 24 days (15-44), 17 days (10-30), and 14 days (5-26), respectively. Ninety percent of patients had BKPyV viremia at the onset of HC with a median viral load of 1850 copies/mL (interquartile range, 240-8550). In multivariable models, high plasma viral load (≥10 000 copies/mL) and cytopenias at the beginning of BKPyV-HC were significantly associated with longer macroscopic hematuria and cystitis symptoms. Use of cidofovir was not associated with shorter duration of illness. In conclusion, BKPyV-HC after allogeneic HCT is characterized by prolonged and severe symptoms and requires improved management strategies. High-grade viremia and cytopenias were associated with a longer duration of BKPyV-associated HC. Accurate descriptions of disease and factors associated with prolonged recovery will inform end points of future clinical trials.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2020        PMID: 32074279      PMCID: PMC7042995          DOI: 10.1182/bloodadvances.2019000802

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  50 in total

1.  BK DNA viral load in plasma: evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients.

Authors:  Veronique Erard; Hyung Woo Kim; Lawrence Corey; Ajit Limaye; Meei-Li Huang; David Myerson; Chris Davis; Michael Boeckh
Journal:  Blood       Date:  2005-04-21       Impact factor: 22.113

2.  The risk of polyomavirus BK-associated hemorrhagic cystitis after allogeneic hematopoietic SCT is associated with myeloablative conditioning, CMV viremia and severe acute GVHD.

Authors:  J Uhm; N Hamad; F V Michelis; M Shanavas; J Kuruvilla; V Gupta; J H Lipton; H A Messner; M Seftel; D D Kim
Journal:  Bone Marrow Transplant       Date:  2014-08-11       Impact factor: 5.483

3.  Cidofovir in the Treatment of BK Virus-Associated Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Michael Philippe; Florence Ranchon; Lila Gilis; Vérane Schwiertz; Nicolas Vantard; Florence Ader; Hélène Labussiere-Wallet; Xavier Thomas; Franck-Emmanuel Nicolini; Eric Wattel; Sophie Ducastelle-Leprêtre; Fiorenza Barraco; Laure Lebras; Gilles Salles; Mauricette Michallet; Catherine Rioufol
Journal:  Biol Blood Marrow Transplant       Date:  2015-12-21       Impact factor: 5.742

4.  Quantification of BK Virus Standards by Quantitative Real-Time PCR and Droplet Digital PCR Is Confounded by Multiple Virus Populations in the WHO BKV International Standard.

Authors:  Allen C Bateman; Alexander L Greninger; Ederlyn E Atienza; Ajit P Limaye; Keith R Jerome; Linda Cook
Journal:  Clin Chem       Date:  2017-01-18       Impact factor: 8.327

5.  Specific delineation of BK polyomavirus in kidney tissue with a digoxigenin-labeled DNA probe.

Authors:  Rachael K Parkin; Michael J Boeckh; Veronique Erard; Meei-Li Huang; David Myerson
Journal:  Mol Cell Probes       Date:  2005-01-06       Impact factor: 2.365

6.  Quantification of polyoma BK viruria in hemorrhagic cystitis complicating bone marrow transplantation.

Authors:  A Y Leung; C K Suen; A K Lie; R H Liang; K Y Yuen; Y L Kwong
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

7.  Relationship between clinical and BK virological response in patients with late hemorrhagic cystitis treated with cidofovir: a retrospective study from the European Group for Blood and Marrow Transplantation.

Authors:  S Cesaro; M Pillon; G Tridello; M Aljurf; R Martino; W Schroyens; C Nozzoli; P Barba; M Faraci; F Fagioli; B Cappelli; C Cordonnier; F Al-Mohareb; Y Floisand; J Greil; I S Panizzolo; S Santarone
Journal:  Bone Marrow Transplant       Date:  2012-12-10       Impact factor: 5.483

8.  BK virus disease after allogeneic stem cell transplantation: a cohort analysis.

Authors:  Nienke M G Rorije; Margaret M Shea; Gowri Satyanarayana; Sarah P Hammond; Vincent T Ho; Lindsey R Baden; Joseph H Antin; Robert J Soiffer; Francisco M Marty
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-22       Impact factor: 5.742

9.  Treatment of BK virus-associated hemorrhagic cystitis with low-dose intravenous cidofovir in patients undergoing allogeneic hematopoietic cell transplantation.

Authors:  Seung-Shin Lee; Jae-Sook Ahn; Sung-Hoon Jung; Seo-Yeon Ahn; Jae-Yong Kim; Hee-Chang Jang; Seung-Ji Kang; Mi-Ok Jang; Deok-Hwan Yang; Yeo-Kyeoung Kim; Je-Jung Lee; Hyeoung-Joon Kim
Journal:  Korean J Intern Med       Date:  2015-02-27       Impact factor: 2.884

10.  A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation.

Authors:  Francisco M Marty; Drew J Winston; Roy F Chemaly; Kathleen M Mullane; Tsiporah B Shore; Genovefa A Papanicolaou; Greg Chittick; Thomas M Brundage; Chad Wilson; Marion E Morrison; Scott A Foster; W Garrett Nichols; Michael J Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2018-10-04       Impact factor: 5.742

View more
  11 in total

1.  BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation.

Authors:  Eduardo Espada; Matthew P Cheng; Haesook T Kim; Ann E Woolley; Jason I Avigan; Edouard Forcade; Maria V D Soares; João F Lacerda; Sarah Nikiforow; Mahasweta Gooptu; Rizwan Romee; Edwin P Alyea; Philippe Armand; Corey S Cutler; Vincent T Ho; John Koreth; Joseph H Antin; Robert J Soiffer; Francisco M Marty; Jerome Ritz
Journal:  Blood Adv       Date:  2020-05-12

2.  Incidence, risk factors and outcome of BK virus hemorrhagic cystitis following allogenic hematopoietic cell transplantation: a retrospective cohort study.

Authors:  Gérard Socié; Jean-Michel Molina; Anastasia Saade; Julien Gras; Michael Darmon; David Michonneau; Nathalie Dhedin; Linda Feghoul; Jérôme Le Goff; Aliénor Xhaard; Régis Peffault De Latour
Journal:  Bone Marrow Transplant       Date:  2022-05-20       Impact factor: 5.174

3.  In Vitro Generation of BK polyomavirus-specific T cells for adoptive cell therapy in refractory cystitis hemorrhagic patients after hematopoietic stem cell transplantation.

Authors:  Maryam Mohammadi Najafabadi; Masoud Soleimani; Mohammad Ahmadvand; Mina Soufi Zomorrod; Seied Asadollah Mousavi
Journal:  BMC Immunol       Date:  2022-06-10       Impact factor: 3.594

4.  Evaluation of a Next-Generation Sequencing Metagenomics Assay to Detect and Quantify DNA Viruses in Plasma from Transplant Recipients.

Authors:  Soya S Sam; Ralph Rogers; Fizza S Gillani; Gregory J Tsongalis; Colleen S Kraft; Angela M Caliendo
Journal:  J Mol Diagn       Date:  2021-03-09       Impact factor: 5.568

5.  BKV Related Hemorrhagic Cystitis-An Insight into Risk Factors and Later Complications-An Analysis on Behalf of Polish Adult Leukemia Group.

Authors:  Jarosław Dybko; Agnieszka Piekarska; Siddarth Agrawal; Sebastian Makuch; Donata Urbaniak-Kujda; Monika Biernat; Blanka Rybka; Magdalena Dutka; Alicja Sadowska-Klasa; Sebastian Giebel; Lidia Gil
Journal:  Cancers (Basel)       Date:  2022-02-01       Impact factor: 6.639

6.  BK Polyomavirus Hemorrhagic Cystitis in Hematopoietic Cell Transplant Recipients.

Authors:  Sharon Anbumalar Lionel; Aby Abraham; Vikram Mathews; Kavitha Lakshmi; Asha Mary Abraham; Biju George
Journal:  J Glob Infect Dis       Date:  2022-02-28

7.  Hemorrhagic cystitis in allogeneic stem cell transplantation: a role for age and prostatic hyperplasia.

Authors:  Eugenio Galli; Federica Sorà; Luca Di Gianfrancesco; Sabrina Giammarco; Elisabetta Metafuni; Maria Assunta Limongiello; Idanna Innocenti; Francesco Autore; Luca Laurenti; Patrizia Chiusolo; Andrea Bacigalupo; Simona Sica
Journal:  Support Care Cancer       Date:  2022-02-18       Impact factor: 3.359

8.  Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients.

Authors:  Adam S Nelson; Daria Heyenbruch; Jeremy D Rubinstein; Anthony Sabulski; Sonata Jodele; Shawn Thomas; Carolyn Lutzko; Xiang Zhu; Thomas Leemhuis; Jose A Cancelas; Michael Keller; Catherine M Bollard; Patrick J Hanley; Stella M Davies; Michael S Grimley
Journal:  Blood Adv       Date:  2020-11-24

Review 9.  Harnessing T Cells to Control Infections After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Sabrina Basso; Francesca Compagno; Paola Zelini; Giovanna Giorgiani; Stella Boghen; Elena Bergami; Jessica Bagnarino; Mariangela Siciliano; Claudia Del Fante; Mario Luppi; Marco Zecca; Patrizia Comoli
Journal:  Front Immunol       Date:  2020-10-15       Impact factor: 7.561

Review 10.  Evaluation and Management of Genitourinary Emergencies in Patients with Cancer.

Authors:  Demis N Lipe; Phillip B Mann; Rodrick Babakhanlou; Maria T Cruz Carreras; A Guido Hita; Monica K Wattana
Journal:  Emerg Med Int       Date:  2021-07-27       Impact factor: 1.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.